VR Logo

Xeris Biopharma Holdings Inc. (XERS) download report


Healthcare | Biotechnology & Pharma Research

Xeris Biopharma Holdings Inc. (XERS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.

IPO Date: 21-Jun-2018

Chairman & CEO: Mr. Paul R. Edick

Pres & COO: Mr. John P. Shannon

Listing: NASDAQ: XERS

Country: United States

Headquarters: Chicago, IL

Website: https://www.xerispharma.com

Key Facts

Market cap: $220.92 Mln

Revenue (TTM): $63.68 Mln

Earnings (TTM): $-138.03 Mln

Cash: $132.15 Mln

Total Debt: $137.98 Mln

Insider's Holding: 2.64%

Liquidity: Low

52 Week range: $1.25 - 4.79

Shares outstanding: 135,531,008

6 Years Aggregate:

  • CFO: $-377.47 Mln
  • EBITDA: $-407.29 Mln
  • Net Profit: $-439.29 Mln

Stock Performance

Time Period Xeris Biopharma Holdings (XERS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-45.05-8.71-16.53
1 month-19.50-3.11-6.32
3 months-43.11-7.30-12.09
1 Year-66.530.48-15.75
3 Years-46.6810.347.56
5 Years--11.436.66
10 Years--12.1010.48
As on 27-Jun-2022 *As on 28-Jun-2022
Year Xeris Biopharma Holdings (XERS) S&P Small-Cap 600 S&P BSE Sensex
2021-40.4525.2721.99
2020-30.219.5715.75
2019-58.5320.8614.38